Dosch Pharmaceuticals Profile
Key Indicators
- Authorised Capital ₹ 3.00 Cr
as on 25-04-2024
- Paid Up Capital ₹ 1.86 Cr
as on 25-04-2024
- Company Age 32 Year, 8 Months
- Last Filing with ROC 31 Mar 2019
- Satisfied Charges ₹ 177.82 Cr
as on 25-04-2024
- Revenue 24.50%
(FY 2018)
- Profit -5442.74%
(FY 2018)
- Ebitda -82.01%
(FY 2018)
- Net Worth -2.36%
(FY 2018)
- Total Assets -20.48%
(FY 2018)
About Dosch Pharmaceuticals
- CIN/LLPIN
U24230MH1992PTC066403
- Company No.
066403
- Company Classification
Private Limited Indian Non-Government Company
- Incorporation Date
20 Apr 1992
- Date of AGM
30 Sep 2019
- Date of Balance Sheet
31 Mar 2019
- Listing Status
Unlisted
- ROC Code
Roc Mumbai
Industry
Company Details
- Location
Mumbai, Maharashtra, India
- Telephone
- Email Address
- Website
- Social Media
What products or services does Dosch Pharmaceuticals Pvt Ltd offer?
Dosch Pharmaceuticals Pvt Ltd offers a wide range of products and services, including Animal Medicines & Health Care, Animal Treatment Services, Cleaning Liquids & Wipes, Surface Cleaner, Nutraceuticals & Dietary Supplements, Mineral Supplement, Veterinary Medicines, Fitness Clubs and Beauty Parlours, Beauty Services, Industrial Chemicals & Supplies.
Who are the key members and board of directors at Dosch Pharmaceuticals?
Executive Team (1)
| Name | Designation | Appointment Date | Status |
|---|---|---|---|
Sanjay Doshi  | Managing Director | 20-Apr-1992 | Current |
Board Members(2)
| Name | Designation | Appointment Date | Status |
|---|---|---|---|
| Ashay Doshi | Director | 02-May-2014 | Current |
| Prachi Doshi | Wholetime Director | 31-Oct-1992 | Current |
Financial Performance of Dosch Pharmaceuticals.
Dosch Pharmaceuticals Pvt Ltd, for the financial year ended 2018, experienced significant growth in revenue, with a 24.5% increase. The company also saw a substantial fall in profitability, with a 5442.74% decrease in profit. The company's net worth dipped by a decrease of 2.36%.
- Key Matrics
- Balance Sheet
- Profit and Loss
- Cash Flow
- Ratios
| Metric |
| (FY 2022) | (FY 2021) | (FY 2020) | (FY 2019) | ||
|---|---|---|---|---|---|---|---|
| Total Revenue |
| ||||||
| Revenue from Operations |
| ||||||
| Total Assets |
| ||||||
| Profit or Loss |
| ||||||
| Net Worth |
| ||||||
| EBITDA |
|
What is the Ownership and Shareholding Structure of Dosch Pharmaceuticals?
In 2018, Dosch Pharmaceuticals had a promoter holding of 100.00%. Access key insights, ownership, including shareholding patterns, funding, foreign investors, KMP remuneration, group structure, and overseas investments.
Related Corporates (Common Directorship)
Dosch Pharmaceuticals Private LimitedActive 29 years 8 monthsAshay Doshi, Sanjay Doshi and 1 more are mutual person
Charges (Loans)
| Lender | Amount | Status |
|---|---|---|
Infina Finance Private Limited Creation Date: 19 Dec 2014 | ₹108.00 Cr | Satisfied |
Kotak Mahindra Investments Limited Creation Date: 17 Oct 2014 | ₹40.00 Cr | Satisfied |
Citicorp Finance India Limited Creation Date: 03 Sep 2004 | ₹0.61 M | Satisfied |
How Many Employees Work at Dosch Pharmaceuticals?
Dosch Pharmaceuticals has a workforce of 10 employees as of Apr 08, 2024. Unlock access to detailed historical data on individuals associated with the company, including employment records, contributions to the Employees' Provident Fund Organization (EPFO), and other related insights.
Deals i
Gain comprehensive insights into the Deals and Valuation data of Dosch Pharmaceuticals, offering detailed information on various transactions, including security allotment data. Explore the intricate details of financial agreements, mergers, acquisitions, divestitures, and strategic partnerships that have shaped Dosch Pharmaceuticals's trajectory.
Rating
Access the credit rating data, providing valuable insights into the company's creditworthiness and financial stability. Explore assessments from leading credit rating agencies, evaluating factors such as debt obligations, liquidity, profitability, and overall financial health.
Alerts
Stay informed about regulatory alerts and litigation involving and associated companies. Receive timely updates on legal proceedings, regulatory changes, and compliance issues that may impact the company's operations, reputation, and financial performance. Monitor litigation involving subsidiaries, joint ventures, and other affiliated entities to assess potential risks and liabilities.
